Author

Adrienne O. van Nieuwenhuizen

Observed names: A van Nieuwenhuizen, A. van Nieuwenhuizen, Adrienne O Van Nieuwenhuizen, Adrienne O van Nieuwenhuizen, Adrienne van Nieuwenhuizen, Van Nieuwenhuizen, Adrienne
Observed institutions: AstraZeneca (United Kingdom), Novartis (Switzerland), Merck & Co., Inc., Rahway, NJ, USA (United States), San Francisco VA Medical Center, United States Food and Drug Administration, National Institute on Drug Abuse, Boehringer Ingelheim (Germany), Harvard University, Janssen (Belgium), Eli Lilly (United States), University of California, San Francisco, Pfizer (United States), King's College London, GlaxoSmithKline (United Kingdom), Sunovion (United Kingdom), University of Cambridge, Sanofi (France), Abbott (United Kingdom), National Center for Complementary and Integrative Health, United BioSource Corporation (United Kingdom), Massachusetts General Hospital, Bristol-Myers Squibb (United States), Jazz Pharmaceuticals (United States), Nutrition 21 (United States), Psychogenics (United States), Alkermes (United States), Sunovion (United States), Brain & Behavior Research Foundation, Epix Pharmaceuticals (United States), Neuronetics (United States), Vanda Pharmaceuticals (United States), Imedex (United States), Wolters Kluwer (Netherlands), University of Michigan–Dearborn, Servier (France), Supernus Pharmaceuticals (United States), PureTech (United States), Cambridgeshire and Peterborough NHS Foundation Trust, Wolters Kluwer Health, Eisai (United States), National Institute of Mental Health, American Psychiatric Association, National Institute of Mental Health, Ganeden Biotech (United States), Covance (United Kingdom), Wyeth, Labopharm Inc. (Canada), ICON PLC (Ireland), FORUM Pharmaceuticals (United States), Orexigen Therapeutics (United States), American Society of Clinical Psychopharmacology, Belvoir Media Group (United States), Organon (Netherlands), Takeda (Japan), Covance (United States), Bayer (Germany), BioMarin (United States), Grünenthal Group (Germany)
ORCID: 0000-0002-5326-1306
Observed ORCID: 0000-0002-5326-1306
OpenAlex ID: A5000465215
2012 · Sarah Clement, Adrienne van Nieuwenhuizen, et al. · The British Journal of Psychiatry · 228
2012 · A. van Nieuwenhuizen, C. Henderson, et al. · Epidemiology and Psychiatric Sciences · 156
2021 · Adrienne van Nieuwenhuizen, Kelsey Hudson, et al. · Current Psychiatry Reports · 137
2010 · Nadia Iovieno, Adrienne van Nieuwenhuizen, et al. · Depression and Anxiety · 107
2012 · Dan G. Blazer, Adrienne O. van Nieuwenhuizen · Current Opinion in Psychiatry · 78
2017 · Shayanti Chattopadhyay, Roger Tait, et al. · EBioMedicine · 49
2015 · Rosemary J. Holt, Julia M. Graham, et al. · Developmental Cognitive Neuroscience · 34
2017 · Jie-Yu Chuang, Cindy C. Hagan, et al. · Frontiers in Psychiatry · 30
2021 · Defne Saatci, Adrienne van Nieuwenhuizen, et al. · Journal of Psychiatric Research · 26
2011 · John W. Denninger, Adrienne O. van Nieuwenhuizen, et al. · The Journal of Nervous and Mental Disease · 24
2009 · John D. Matthews, Caleb Siefert, et al. · Journal of Clinical Psychopharmacology · 23
2009 · Andrew A. Nierenberg, Madhukar H. Trivedi, et al. · Australian & New Zealand Journal of Psychiatry · 11
2019 · Ellen R. Bradley, Adrienne van Nieuwenhuizen, et al. · Schizophrenia Research · 9
2022 · Defne Saatci, Thomas Johnson, et al. · Brain Behavior & Immunity - Health · 8
2012 · Claire Henderson, Adrienne van Nieuwenhuizen, et al. · PsycEXTRA Dataset · 4
2011 · C Henderson, A van Nieuwenhuizen, et al. · Psychiatrische Praxis · 1
2013 · J.A. Graham, Cindy C. Hagan, et al. · F1000Research
2013 · Judith Graham, Cindy C. Hagan, et al. · Biological Psychiatry
2013 · Jheanell Gabbidon, Sarah Clement, et al. · PsycTESTS Dataset
2012 · Sarah Clement, Adrienne van Nieuwenhuizen, et al. · PsycEXTRA Dataset
Works count: 33
Citation count: 1,276
H-index: 16
I10-index: 17
Year
Topic
Type